Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2018. Refer to TA550: Vandetanib for treating medullary thyroid cancer for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | vandetanib (Caprelsa®) | ||
| Formulation | 100 mg and 300 mg film-coated tablet | ||
| Reference number | 427 | ||
| Indication | Treatment of aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. For patients in whom rearranged during transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision |
||
| Company | Genzyme Therapeutics | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Superseded | ||
| Advice number | 2514 | ||
| NMG meeting date | 23/07/2014 | ||
| AWMSG meeting date | 03/09/2014 | ||
| Ratification by Welsh Government | 24/09/2014 | ||
| Date of issue | 25/09/2014 | ||
| Date of last review | 13/12/2017 | ||
| NICE guidance | |||